{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:35:20Z","timestamp":1790681720488,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:00:00Z","timestamp":1460764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40265-016-0577-0","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T03:20:47Z","timestamp":1460776847000},"page":"823-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Obiltoxaximab: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"issue":"8","key":"577_CR1","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/toxins3081004","volume":"3","author":"Z Chen","year":"2011","unstructured":"Chen Z, Moayeri M, Purcell R. Monoclonal antibody therapies against anthrax. Toxins. 2011;3(8):1004\u201319.","journal-title":"Toxins."},{"key":"577_CR2","doi-asserted-by":"crossref","unstructured":"Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):[article no. e130687].","DOI":"10.3201\/eid2002.130687"},{"key":"577_CR3","unstructured":"US Food and Drug Administration. FDA approves new treatment for inhalation anthrax [media release]. 21 March 2016. http:\/\/www.fda.gov ."},{"key":"577_CR4","unstructured":"Elusys Therapeutics Inc. Anthim\u00ae (obiltoxaximab) injection, for intravenous use: US prescribing Information. 2016. http:\/\/www.fda.gov . Accessed 23 Mar 2016."},{"key":"577_CR5","unstructured":"Elusys Therapeutics Inc. Elusys CEO to testify on biodefense before house subcommittee [media release]. 21 Oct 2001. http:\/\/www.prnewswire.com ."},{"key":"577_CR6","unstructured":"Elusys Therapeutics Inc. Elusys submits IND to initiate human studies of anthrax drug; major milestone in company\u2019s development of Anthim [media release]. 28 Feb 2005. http:\/\/www.businesswire.com ."},{"key":"577_CR7","unstructured":"University of Texas at Austin. University of Texas at Austin, Southwest Foundation for Biomedical Research and Elusys Therapeutics test complete anthrax antidote in animals [media release]. 2 Oct 2002. http:\/\/www.engr.utexas.edu\/news ."},{"key":"577_CR8","unstructured":"Elusys Therapeutics Inc. Elusys and US Army extend biodefense collaboration [media release]. 13 Dec 2006. http:\/\/prnewswire.com ."},{"key":"577_CR9","unstructured":"Elusys Therapeutics Inc. NIAID\/BARDA awards Elusys a $12 million contract to further develop Anthim, the company\u2019s anthrax therapeutic [media release]. 25 Sep 2007. http:\/\/www.prnewswire.com ."},{"key":"577_CR10","unstructured":"Elusys Therapeutics Inc. Elusys receives contract for up to $143 million from the US federal government to fund advanced development of Anthim\u00ae, a new treatment for anthrax [media release]. 4 Jan 2010. http:\/\/www.elusys.com ."},{"key":"577_CR11","unstructured":"Elusys Therapeutics Inc. Elusys awarded additional $40.6 million under existing US government contract to fund advanced development of Anthim, a new treatment for anthrax [media release]. 4 Aug 2010. http:\/\/www.elusys.com ."},{"key":"577_CR12","unstructured":"Elusys Therapeutics Inc., Lonza. Elusys Therapeutics and Lonza extend manufacturing agreement for Anthim, a new anthrax treatment in late-stage development [media release]. 15 July 2010. http:\/\/www.elusys.com ."},{"key":"577_CR13","unstructured":"Elusys Therapeutics Inc. Elusys awarded $68 million contract to develop Anthim for intramuscular pre- and post-exposure prophylaxis of anthrax infection [media release]. 8 Sep 2011. http:\/\/www.elusys.com ."},{"key":"577_CR14","unstructured":"Elusys Therapeutics Inc. Elusys awarded additional $50.2 million under an exisiting US government contract to support final stages of development of ETI-204, for treatment of inhalational anthrax [media release]. 2 Aug 2012. http:\/\/www.elusys.com ."},{"key":"577_CR15","unstructured":"Elusys Therapeutics Inc. Elusys awarded additional $14.5 million under existing US government contracts supporting expanded human safety studies of ETI-204 for treatment of inhalational anthrax [media release]. 13 Sep 2012. http:\/\/www.elusys.com ."},{"key":"577_CR16","unstructured":"Elusys Therapeutics Inc. Elusys awarded additional $16 million under existing US government contract to complete development of lyophilized form of Anthim\u00ae (obiltoxaximab) for treatment of inhalational anthrax [media release]. 6 Oct 2015. http:\/\/www.elusys.com ."},{"key":"577_CR17","unstructured":"Elusys Therapeutics Inc. Elusys Therapeutics receives first delivery order from US government for Anthim\u00ae (obiltoxaximab) for treatment of inhalational anthrax [media release]. 12 Nov 2015. http:\/\/www.elusys.com ."},{"key":"577_CR18","unstructured":"Elusys Therapeutics Inc. Elusys Therapeutics receives FDA approval for Anthim\u00ae (obiltoxaximab) injection for the treatment and prophylaxis of inhalational anthrax [media release]. 21 Mar 2016. http:\/\/www.elusys.com ."},{"key":"577_CR19","unstructured":"US Patent and Trademark Office. US patent 8,093,360. 2012. http:\/\/ptft.uspto.gov . Accessed 12 Apr 2016."},{"key":"577_CR20","unstructured":"Elusys Therapeutics Inc. Elusys receives notice of allowance from US Patent Office for methods of preventing or treating anthrax with ETI-204, an anti-anthrax antibody, via intramuscular injection [media release]. 10 Mar 2014. http:\/\/www.elusys.com ."},{"issue":"2","key":"577_CR21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","volume":"73","author":"N Mohamed","year":"2005","unstructured":"Mohamed N, Clagett M, Li J, et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun. 2005;73(2):795\u2013802.","journal-title":"Infect Immun."},{"key":"577_CR22","unstructured":"Carpenter S, Serbina N, Yamamoto B, et al. Obiltoxaximab (ETI-204), a high affinity monoclonal antibody to protective antigen, rapidly reduces toxin levels and promotes bacterial clearance during Bacillus anthracis infection [abstract no. 211 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2015."},{"key":"577_CR23","unstructured":"Serbina N, Shadiack A, O\u2019Connor E, et al. Rabbit model of anthrax for exploring complementarity of antitoxin\/antibiotic combination therapy on survival and development of adaptive immunity [abstract no. 101B]. In: Bacillus ACT\u2014International Anthrax Conference, 2013."},{"key":"577_CR24","unstructured":"Shadiack A, O\u2019Connor E, Carpenter S, et al. Detection of endogenous anti-PA antibodies in anthrax-infected rabbits after treatment with ETI-204 [abstract no. 99C]. In: Bacillus ACT\u2014International Anthrax Conference, 2013."},{"key":"577_CR25","unstructured":"Serbina N, Shadiack A, O\u2019Connor E, et al. Adaptive immunity in rabbits lethally challenged with Bacillus anthracis spores and treated with ETI-204: a monoclonal antibody against protective antigen [abstract no. 217 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2014."},{"key":"577_CR26","unstructured":"Guttendorf R, Mondick J, Serbina N, et al. Animal to human dose translation under the animal rule\u2014obiltoxaximab (ETI-204) case study [abstract no. 111 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2016."},{"key":"577_CR27","unstructured":"Tang H, Mondick J, O\u2019Connor E, et al. Pharmacokinetics of ETI-204, an anti-PA monoclonal antibody, in healthy and anthrax-infected rabbits and monkeys following IV and IM administration [abstract no. 100A]. In: Bacillus ACT\u2014International Anthrax Conference, 2013."},{"key":"577_CR28","unstructured":"Elusys Therapeutics Inc. Elusys Therapeutics presents efficacy results and other key findings on ETI-204 anthrax anti-toxin [media release]. 5 Sep 2013. http:\/\/www.elusys.com ."},{"key":"577_CR29","unstructured":"Nagy C, Mondick J, Czech A, et al. Safety, pharmacokinetics and immunogenicity of intramuscular (IM) administration of obiltoxaximab (ETI-204) to healthy humans [abstract no. 112 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2016."},{"key":"577_CR30","unstructured":"Strout V, Casey L, Nardone L, et al. ETI-204, a monoclonal antibody with high affinity against protective antigen produced by anthrax, is well-tolerated and safe when administered alone or with ciprofloxacin in healthy volunteers [abstract no. B-584]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006."},{"key":"577_CR31","unstructured":"Elusys Therapeutics Inc. Elusys announces results from three phase 3 safety studies of its anthrax anti-toxin, obiltoxaximab (ETI-204), in adult volunteers and completion of its phase 3 clinical development program [media release]. 22 Sep 2014, http:\/\/www.elusys.com ."},{"key":"577_CR32","unstructured":"Sanford D, Koo E, D\u2019Alia G, et al. ETI-204 provides a dramatic improvement in survival at the onset of active anthrax disease and is well tolerated in nonhuman primates [abstract no. F1-3960]. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America\u2014a joint meeting, 2008."},{"key":"577_CR33","unstructured":"Casey LS, Porter J, Hulmes J, et al. ETI-204 anti-toxin monoclonal antibody treatment of active anthrax disease in rabbits [abstract no. 134B plus poster]. In: Bacillus ACT\u2014International Anthrax Conference, 2009."},{"key":"577_CR34","unstructured":"Yamamoto B, Serbina N, Carpenter S, et al. Obiltoxaximab (ETI-204) efficacy across a spectrum of disease severity in a trigger-to-treat cynomolgus monkey inhalational aerosol challenge model of anthrax [abstract no. 092 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2015."},{"issue":"4","key":"577_CR35","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.04593-14","volume":"59","author":"B Biron","year":"2015","unstructured":"Biron B, Beck K, Dyer D, et al. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015;59(4):2206\u201314.","journal-title":"Antimicrob Agents Chemother."},{"key":"577_CR36","unstructured":"Serbina N, Stark G, Fisher A, et al. The use of meta-analysis approach to demonstrate added benefit of obiltoxaximab (ETI-204) in treatment of inhalational anthrax [abstract no. 110 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2016."},{"key":"577_CR37","unstructured":"Yamamoto BJ, Shadiack AM, O\u2019Connor EF, et al. Prophylactic efficacy of IM administered ETI-204 in an inhalational monkey aerosol challenge model of Bacillus anthracis [abstract no. 133]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2014."},{"key":"577_CR38","unstructured":"Casey LS, Jones SM, Curtis K, et al. Intramuscular administration of a high-affinity anti-protective antigen MAb enhances post-exposure antibiotic efficacy against lethal B. anthracis spore challenge [abstract]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2006."},{"key":"577_CR39","unstructured":"Casey L, Hulmes J, Middleton J, et al. Evaluation of the efficacy of ETI-204 when administered intramuscularly in a rabbit post-exposure spore challenge model [abstract no. 55 plus poster]. In: Bacillus ACT\u2014International Anthrax Conference, 2011."},{"key":"577_CR40","unstructured":"Serbina N, Shadiack A, O\u2019Connor E, et al. Efficacy of intramuscularly (IM) administered anti-toxin in preventing inhalational anthrax-related mortality in the cynomolgus model of Bacillus anthracis infection [abstract no. 122 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2013."},{"key":"577_CR41","unstructured":"Serbina N, Yamamoto B, Carpenter S, et al. Obiltoxaximab (ETI-204), demonstrates significant efficacy in primates when given intramuscularly after exposure to inhalational anthrax [abstract no. 209 (G) plus poster]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2015."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0577-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0577-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0577-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:48Z","timestamp":1559490108000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0577-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0577-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,16]]}}}